Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Other solid neoplasm 1Myeloid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Primary Myelofibrosis 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia 1Glioblastoma 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 4tazemetostat 2pembrolizumab 2Rituximab 2Itraconazole 2Cyclophosphamide 2Cisplatin 2vandetanib 1utomilumab 1temsirolimus 1sargramostim 1ruxolitinib 1motexafin gadolinium 1motesanib diphosphate 1fludarabine 1enzalutamide 1entinostat 1carboxyamido-triazole 1avelumab 1Watchful Waiting 1Vorinostat 1Topotecan 1Thalidomide 1Ritonavir 1Rifampin 1Radiotherapy 1Polymerase Chain Reaction 1Pemetrexed 1Paclitaxel 1PF06821497 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × ruxolitinib × Thoracic × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡